Ramiven 50MG Tablet, containing the active ingredient Abemaciclib at a dosage of 50mg, is a targeted therapy primarily used in the treatment of certain types of breast cancer, particularly hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer. This medication is often prescribed for patients who have received prior endocrine therapy or for those with advanced or metastatic disease. Ramiven works by inhibiting specific proteins involved in cancer cell growth, thereby slowing down or stopping the proliferation of cancer cells. The tablet is typically available in a pack of seven, making it convenient for patients to manage their treatment regimen. As a part of a comprehensive cancer treatment plan, Ramiven is crucial for improving patient outcomes and enhancing the quality of life for those battling this challenging disease.